단백질 및 단백질 결정 시장 : 제품 유형별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The global protein and protein crystals market is projected to reach USD 960.37 billion by 2030 from USD 609.51 billion in 2025, at a CAGR of 9.5% from 2025 to 2030.

The protein and protein crystals market is primarily driven by the growing demand for biopharmaceuticals, increasing R&D in structural biology and drug discovery, and the rising use of proteins in diagnostics, therapeutics, and industrial applications. Enzymatic proteins lead the market due to their wide use in therapeutics, industrial biocatalysis, and high-throughput screening, while recombinant and monoclonal proteins drive demand in drug development and personalized medicine because of their specificity and scalability.

Additionally, the growing adoption of protein crystallization kits, reagents, and automated crystallization platforms for structural studies further fuels the market, as researchers and pharmaceutical companies increasingly rely on these products to determine protein structures, accelerate drug design, and enhance enzyme-based industrial processes.

By product type, the structural proteins segment is expected to register the highest CAGR during the forecast period.

By product type, the structural proteins segment is expected to account for the highest CAGR in the protein and protein crystals market. The growth of the structural proteins segment in the protein and protein crystals market is driven by multiple factors across research, healthcare, and industrial applications. Research proteins such as actin and tubulin are in high demand for structural biology, high-throughput crystallography, and drug discovery, enabling precise protein structure determination and rational drug design. Membrane proteins are increasingly sought after as critical therapeutic targets in the development of biologics and precision medicine. Connective tissue and extracellular matrix proteins, including collagen, elastin, laminins, and proteoglycans, are fueling demand in biomaterials, tissue engineering, and regenerative medicine, as well as in cosmetic and healthcare products.

By application, the healthcare segment accounted for the highest CAGR of the market in 2024.

The healthcare application segment is expected to register the highest CAGR in the proteins and protein crystals market due to the increasing demand for therapeutic proteins, monoclonal antibodies, vaccines, and diagnostic enzymes. Growing prevalence of chronic diseases, cancer, and metabolic disorders is driving the development and use of protein-based biologics, while advances in structural biology and protein crystallography are accelerating drug discovery and targeted therapy. Rising investments in biopharmaceutical R&D, clinical research, and high-throughput protein analysis are fueling the adoption of protein crystals and related products in healthcare, making this segment the fastest-growing compared with industrial, food, and research applications. as therapeutic and structural proteins are increasingly being used in biologics development. The rising incidence of hereditary and chronic diseases is driving the need for protein-based treatments. Precise structure-based drug design is made possible by developments in protein crystallography, which drives biopharmaceutical innovation. Expanding clinical applications and higher R&D expenditures also contribute to this market's growth.

Asia Pacific is expected to register the highest growth rate in the market during the forecast period.

The Asia-Pacific region is expected to register the highest CAGR in the protein and protein crystals market due to strong growth across healthcare, research, and other applications. In healthcare, increasing biopharmaceutical R&D, rising prevalence of chronic diseases, and adoption of personalized medicine are driving demand for therapeutic proteins, monoclonal antibodies, and protein-based diagnostics. In research and academia, expanding life sciences infrastructure, CROs, and structural biology initiatives boost the use of protein crystallization kits and reagents. Other applications are contributing to market growth, in agriculture and animal health, proteins and enzymes are used for feed additives, vaccines, and disease management; in cosmetics, structural proteins like collagen and elastin are applied in anti-aging and skincare products; and in bioenergy, enzymes facilitate biomass conversion and biofuel production. The combined demand across healthcare, research, agriculture, animal health, cosmetics, and bioenergy is fueling rapid market growth in Asia-Pacific.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (55%), Directors (27%), and Others (18%)

By Region: North America (35%), Europe (32%), Asia Pacific (25%), Latin America (6%), and the Middle East & Africa (2%)

The prominent players in this market are Danaher (US), Thermo Fischer Scientific inc. (US), Sanofi (France), Agilent (US), Takeda Pharmaceutical Company (Japan), International Flavours and Fragrances (US), Biocon (India), RayBiotech (US), Merck KGaA (Germany), Amgen (US), Eli lilly (US), Roche (Switzerland), Novo Nordisk (Denmark), and Pfizer (US), among others.

Research Coverage

The protein and protein crystals market is segmented by product type, application, end user, and region. Key factors influencing market growth include driving forces, restraints, opportunities, and challenges for stakeholders. The report also reviews the leading companies competing in the Protein and Pprotein Ccrystals market. A micro-level analysis can be conducted to examine trends, growth opportunities, and contributions to the market. Additionally, it highlights potential revenue growth opportunities across various market segments in five major regions.

Key Benefits of Buying the Report

The report is valuable for new entrants in the protein and protein crystals market as it provides comprehensive information about the market. This information is essential for understanding various investment opportunities. The report provides insights into both key and smaller players in the market, which can help create a solid basis for risk analysis when making investment decisions. It accurately segments the market by end users and regions, providing focused insights into specific market segments. Additionally, the report highlights key trends, challenges, growth drivers, and opportunities to support strategic decision-making through a thorough analysis.

The report provides insights into the following points:

• Key drivers (Rising demand for therapeutic proteins, Advancements in protein crystallization and structural biology, increasing applications in food processing and industrial biotechnology), restraints (High production and purification costs, Limited stability and storage of protein-based products), opportunities (Emergence of AI and automation in protein crystallography, Integration of hybrid and 3D printing technologies, Collaborations between academia and industry), and challenges (reproducibility issues in protein crystallization, Competition from alternative analytical techniques)
• Product Development/Innovation: Emerging technologies in space, R&D, recent product launches & approvals in the protein and protein crystals market.
• Market Growth: In-depth insights into remunerative markets report analyze the protein and protein crystals market across varied geographies.
• Market Diversification: Detailed analysis of new products, unexplored geographies, latest trends, and investments in the protein and protein crystals market
• Competitive Assessment: Detailed assessment of market share, service offerings, leading strategies of major players such as Danaher (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La F. Hoffmann-La Roche AG (Switzerland), Roche Ltd (Germany), Amgen (US) and Merck KGaA (Germany), among others..

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN PROTEINS & PROTEIN CRYSTALS MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 PROTEINS & PROTEIN CRYSTALS MARKET OVERVIEW
• 3.2 VALUE CHAIN ANALYSIS OF PROTEINS & PROTEIN CRYSTALS MARKET
• 3.3 NORTH AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION AND END USER, 2025
• 3.4 GEOGRAPHIC SNAPSHOT OF PROTEINS & PROTEIN CRYSTALS MARKET

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing emphasis on structure-based drug discovery and development
    • 4.2.1.2 Rising demand for protein-based drug development
    • 4.2.1.3 Increasing demand for therapeutic proteins
    • 4.2.1.4 Technological advancements in crystallization methods
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High technical complexity and low success rates in protein crystallization
    • 4.2.2.2 Exposure to ionizing radiation and contrast-related concerns among vulnerable populations
    • 4.2.2.3 Need for high costs, technical expertise, and advanced infrastructure for commercialization
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Integration of AI-enabled innovations
    • 4.2.3.2 Collaboration between academia and industry
    • 4.2.3.3 High investment and funding in structural biology, biopharmaceuticals, and advanced drug development
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Reproducibility issues in protein crystallization
    • 4.2.4.2 Scalability concerns in recombinant protein production
• 4.3 UNMET NEEDS
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF BUYERS
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 GDP TRENDS & FORECAST
  • 5.2.2 TRENDS IN GLOBAL ENVIRONMENTAL INDUSTRY
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
  • 5.3.1 PROMINENT COMPANIES
  • 5.3.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.3.3 END USERS
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 RESEARCH & DEVELOPMENT
  • 5.4.2 MANUFACTURING
  • 5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE OF PROTEINS & PROTEIN CRYSTALS, BY PRODUCT, 2024
  • 5.6.2 AVERAGE SELLING PRICE TREND OF PROTEINS & PROTEIN CRYSTALS, BY REGION, 2022-2024
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA FOR HS CODE 3507, 2021-2024
  • 5.7.2 EXPORT DATA FOR HS CODE 3507, 2021-2024
  • 5.7.3 TRADE ANALYSIS FOR HS CODE 293719
• 5.8 KEY CONFERENCES & EVENTS, 2025-2026
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 COMPUTATIONAL DESIGN OF HIGH-AFFINITY MINIBINDER PROTEINS FOR THERAPEUTIC TARGETS
• 5.12 IMPACT OF 2025 US TARIFF ON PROTEINS & PROTEIN CRYSTALS MARKET
  • 5.12.1 KEY TARIFF RATES
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUNTRY/REGION
    • 5.12.4.1 North America
      • 5.12.4.1.1 US
    • 5.12.4.2 Europe
    • 5.12.4.3 Asia Pacific
  • 5.12.5 IMPACT ON END-USE INDUSTRIES

6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 CRYO-CRYSTALLIZATION
  • 6.1.2 X-RAY FREE-ELECTRON LASERS (XFELS)
  • 6.1.3 COMPUTATIONAL PROTEIN DESIGN TOOLS
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 MICROFLUIDICS AND LAB-ON-A-CHIP (LOC) TECHNOLOGIES
  • 6.2.2 NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY
• 6.3 PATENT ANALYSIS
• 6.4 IMPACT OF AI/GEN AI ON PROTEINS & PROTEIN CRYSTALS MARKET
  • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.4.2 BEST PRACTICES IN PROTEINS & PROTEIN CRYSTALS MARKET
  • 6.4.3 CASE STUDIES
  • 6.4.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
  • 6.4.5 CLIENT'S READINESS TO ADOPT GEN AI IN PROTEINS & PROTEIN CRYSTALS MARKET
• 6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS
• 6.6 REGULATORY LANDSCAPE
  • 6.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 6.7 INDUSTRY STANDARDS
• 6.8 CERTIFICATIONS, LABELLING, AND ECO-STANDARDS
  • 6.8.1 CERTIFICATIONS & GOOD MANUFACTURING/QUALITY STANDARDS
  • 6.8.2 LABELLING & TRACEABILITY
  • 6.8.3 ECO-STANDARDS/ENVIRONMENTAL/SUSTAINABILITY CERTIFICATION
• 6.9 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR
  • 6.9.1 DECISION-MAKING PROCESS
• 6.10 KEY STAKEHOLDERS & BUYING CRITERIA
  • 6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 6.10.2 KEY BUYING CRITERIA
• 6.11 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 6.12 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

7 PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE

• 7.1 INTRODUCTION
• 7.2 ENZYMATIC PROTEINS
  • 7.2.1 INDUSTRIAL ENZYMES
    • 7.2.1.1 Focus on green manufacturing and sustainable solutions to aid adoption
  • 7.2.2 FOOD ENZYMES
    • 7.2.2.1 Expansion of food-based technologies to propel market growth
• 7.3 THERAPEUTIC PROTEINS
  • 7.3.1 MONOCLONAL ANTIBODIES
    • 7.3.1.1 Advancing disease targeting and treatment through monoclonal antibody technologies to spur adoption
  • 7.3.2 INSULIN
    • 7.3.2.1 Strengthening investment scenario for insulin development to fuel market growth
  • 7.3.3 HORMONES
    • 7.3.3.1 Introduction of new drugs and therapies for hormonal diseases to propel segment growth
  • 7.3.4 COAGULATION FACTORS
    • 7.3.4.1 Enhanced hemostasis therapies through advanced coagulation protein technologies to augment market growth
• 7.4 STRUCTURAL PROTEINS
  • 7.4.1 RESEARCH PROTEINS
    • 7.4.1.1 Research proteins to empower drug discovery and molecular research with AI integration
  • 7.4.2 STRUCTURAL PROTEINS
    • 7.4.2.1 Advancements in structural protein through collagen and connective tissue insights to fuel market growth
• 7.5 SPECIALTY PROTEINS
  • 7.5.1 INDUSTRIAL PROTEINS
    • 7.5.1.1 Industrial proteins to optimize industrial processes through advanced protein technologies
  • 7.5.2 NUTRITIONAL PROTEINS
    • 7.5.2.1 Nutritional proteins to enable evidence-based, disease-specific nutrition for complementing pharmaceutical therapies
  • 7.5.3 ANALYTICAL PROTEINS
    • 7.5.3.1 Analytical proteins to support quality control and scientific discovery
  • 7.5.4 COSMECEUTICAL PROTEINS
    • 7.5.4.1 Focus on innovative personal care products to support segment growth
  • 7.5.5 FUNTIONAL FOOD PROTEINS
    • 7.5.5.1 Functional foods & beverages with advanced proteins to improve digestibility of nutritional profile

8 PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 HEALTHCARE
  • 8.2.1 ADVANCEMENTS IN PROTEIN ENGINEERING, STRUCTURAL BIOLOGY, AND HIGH-THROUGHPUT CRYSTALLIZATION TO SPUR MARKET
• 8.3 TISSUE ENGINEERING
  • 8.3.1 DEVELOPMENT OF ADVANCED REGENERATIVE MEDICINE THROUGH PROTEIN-BASED TISSUE ENGINEERING TO AID MARKET GROWTH
• 8.4 AGRICULTURE & ANIMAL NUTRITION
  • 8.4.1 FOCUS ON BETTER AGRICULTURAL PRODUCTIVITY AND ANIMAL HEALTH THROUGH PROTEIN-BASED SOLUTIONS TO DRIVE MARKET
• 8.5 INDUSTRIAL PROCESSING
  • 8.5.1 GROWING DEMAND FOR HIGH-PERFORMANCE AND ECO-FRIENDLY PRODUCTS TO DRIVE MARKET GROWTH
• 8.6 BIOENERGY & ENVIRONMENTAL
  • 8.6.1 GROWING DEMAND FOR SUSTAINABLE ENERGY AND ECO-FRIENDLY SOLUTIONS TO BOOST MARKET GROWTH
• 8.7 COMECEUTICALS & NUTRACEUTICALS
  • 8.7.1 ADVANCEMENTS IN PROTEIN-BASED NUTRACEUTICALS TO ENHANCE DIGESTIBILITY AND NUTRIENT DELIVERY
• 8.8 OTHER APPLICATIONS

9 PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMA INDUSTRY
  • 9.2.1 DRUG DEVELOPMENT
    • 9.2.1.1 Increased internal biologics discovery and process-development activity to augment market growth
  • 9.2.2 FORMULATION/MANUFACTURING
    • 9.2.2.1 Advancing protein therapeutics through optimized formulation and manufacturing to propel segment growth
  • 9.2.3 STORAGE/INVENTORY MANAGEMENT
    • 9.2.3.1 Optimal storage/inventory management to optimize supply, reduce waste, and prevent stockouts
• 9.3 BIOTECHNOLOGY INDUSTRY
  • 9.3.1 DRUG DEVELOPMENT
    • 9.3.1.1 Growth of precision/personalized medicines and advanced therapeutics to aid segment growth
  • 9.3.2 FORMULATION/MANUFACTURING
    • 9.3.2.1 Expansion of manufacturing facilities in biotechnology industry leading to support market growth
  • 9.3.3 STORAGE/INVENTORY MANAGEMENT
    • 9.3.3.1 Optimizing storage and inventory management for proteins and protein crystals to enhance safety, quality, and accessibility
• 9.4 RESEARCH, ACADEMIA, AND CROS
  • 9.4.1 DRUG DEVELOPMENT & DISCOVERY
    • 9.4.1.1 Focus on accelerating advancements protein & protein crystal applications to fuel segment growth
  • 9.4.2 LIFE SCIENCE RESEARCH
    • 9.4.2.1 Expanding scope of research for formulating targeted treatment strategies to boost Market
• 9.5 FOOD & BEVERAGE INDUSTRY
  • 9.5.1 INCREASING DEMAND FOR HIGH PROTEIN DIETS, NUTRITIONAL SUPPLEMENTS, AND FUNCTIONAL FOODS TO AID MARKET GROWTH
• 9.6 OTHER END USERS

10 PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 US
    • 10.2.1.1 US to dominate North American proteins & protein crystals market during study period
  • 10.2.2 CANADA
    • 10.2.2.1 Innovations in protein AI to drive advanced protein design and structure prediction
• 10.3 EUROPE
  • 10.3.1 GERMANY
    • 10.3.1.1 Favorable healthcare policies and regulatory landscape to drive market
  • 10.3.2 UK
    • 10.3.2.1 Favorable regulatory scenario for protein & protein crystal development to support market growth
  • 10.3.3 FRANCE
    • 10.3.3.1 Increased healthcare funding by government bodies to aid market growth
  • 10.3.4 ITALY
    • 10.3.4.1 Increased availability of reimbursement coverage for proteins and protein crystals to augment market growth
  • 10.3.5 SPAIN
    • 10.3.5.1 Ongoing research linking crystallography to disease mechanisms and infrastructure development to aid market growth
  • 10.3.6 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 CHINA
    • 10.4.1.1 Emphasis on modernization and expansion of healthcare infrastructure to drive market
  • 10.4.2 JAPAN
    • 10.4.2.1 Rise in research applications using proteins & protein crystals to propel market growth
  • 10.4.3 INDIA
    • 10.4.3.1 Investments and funding activities in Indian biotechnology and biopharma industry to augment market growth
  • 10.4.4 AUSTRALIA
    • 10.4.4.1 Rising investments in healthcare infrastructure to drive market
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Strong academic & research infrastructure and favorable national funding programs to aid market growth
  • 10.4.6 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 BRAZIL
    • 10.5.1.1 Growing adoption of proteins in research centers and workshops to propel market growth
  • 10.5.2 MEXICO
    • 10.5.2.1 Increasing investments and funding for development and manufacturing of protein-based APIs to drive market
  • 10.5.3 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 GCC COUNTRIES
    • 10.6.1.1 Government initiatives for better digital health and improved telemedicine to drive market
  • 10.6.2 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEINS & PROTEIN CRYSTALS MARKET
• 11.3 REVENUE ANALYSIS, 2021-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY VALUATION & FINANCIAL METRICS
  • 11.5.1 FINANCIAL METRICS
  • 11.5.2 COMPANY VALUATION
• 11.6 BRAND/PRODUCT COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.7.5.1 Company footprint
    • 11.7.5.2 Region footprint
    • 11.7.5.3 Product footprint
    • 11.7.5.4 Application footprint
    • 11.7.5.5 End-user footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES (2024)
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.8.5.1 Detailed list of key startups/SMEs
    • 11.8.5.2 Competitive benchmarking of key startups/SMEs
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 DANAHER CORPORATION
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
      • 12.1.1.3.2 Expansions
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 RAYBIOTECH, INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 MERCK & CO., INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 AMGEN INC.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 ELI LILLY AND COMPANY
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product approvals
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches & approvals
    • 12.1.6.4 Recent developments
      • 12.1.6.4.1 Deals
  • 12.1.7 NOVO NORDISK A/S
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 PFIZER INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product approvals
      • 12.1.8.3.2 Deals
  • 12.1.9 THERMO FISHER SCIENTIFIC INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 SANOFI
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 AGILENT TECHNOLOGIES, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
      • 12.1.11.3.2 Expansions
  • 12.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product approvals
  • 12.1.13 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF)
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches & approvals
      • 12.1.13.3.2 Deals
      • 12.1.13.3.3 Expansions
  • 12.1.14 BIOCON
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product approvals
      • 12.1.14.3.2 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 AMANO ENZYME INC.
  • 12.2.2 ULTREZE ENZYMES
  • 12.2.3 NEOGEN
  • 12.2.4 BIOLAXI ENZYMES PVT. LTD.
  • 12.2.5 GENSCRIPT
  • 12.2.6 BIOSEUTICA
  • 12.2.7 KERRY GROUP PLC
  • 12.2.8 ASSOCIATED BRITISH FOODS PLC
  • 12.2.9 K-GENIX GROUP
  • 12.2.10 NAGASE & CO., LTD.
  • 12.2.11 GRIFOLS, S.A
  • 12.2.12 BASF
  • 12.2.13 BIO-CAT
  • 12.2.14 AMCO PROTEINS
  • 12.2.15 PROTALIX BIOTHERAPEUTICS

13 RESEARCH METHODOLOGY

• 13.1 RESEARCH DATA
  • 13.1.1 SECONDARY RESEARCH
    • 13.1.1.1 Key secondary sources
    • 13.1.1.2 Objectives of secondary research
    • 13.1.1.3 Key data from secondary sources
  • 13.1.2 PRIMARY RESEARCH
    • 13.1.2.1 Key primary sources
    • 13.1.2.2 Key objectives of primary research
    • 13.1.2.3 Key industry insights
• 13.2 MARKET SIZE ESTIMATION APPROACH
  • 13.2.1 COMPANY REVENUE ESTIMATION APPROACH
  • 13.2.2 CUSTOMER-BASED MARKET ESTIMATION
  • 13.2.3 TOP-DOWN APPROACH
• 13.3 MARKET FORECASTING APPROACH
• 13.4 DATA TRIANGULATION
• 13.5 MARKET SHARE ASSESSMENT
• 13.6 STUDY ASSUMPTIONS
• 13.7 RESEARCH LIMITATIONS
• 13.8 RISK ANALYSIS

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS